Nektar Therapeutics Stock Plunges on Earnings, Disclosure of Drug Trial Issues - Barron's

Nektar Therapeutics Stock Plunges on Earnings, Disclosure of Drug Trial Issues  Barron's

Shares of biotech firm Nektar Therapeutics collapsed after the company revealed in an earnings call that there had been manufacturing issues in two batches of ...

View full coverage on Google News
by via Top stories - Google News